ReviewFrontiers in immunology2026
Combining advanced radiotherapy techniques and immunotherapy: immunomodulatory mechanisms and clinical prospects.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiotherapy synergizes with CD24 blockade to initiate macrophage-driven systemic antitumor immunity in non-small cell lung cancer.Experimental hematology & oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review systematically explores the mechanisms and clinical prospects of combining advanced radiotherapy techniques-including stereotactic body radiotherapy, FLASH radiotherapy, proton therapy, carbon ion radiotherapy, and spatially fractionated radiotherapy-with immunotherapy. It elucidates how radiotherapy activates systemic antitumor immunity by inducing immunogenic cell death, activating the cGAS-STING pathway, upregulating MHC-I expression, and remodeling the tumor microenvironment. These mechanisms synergize with immune checkpoint inhibitors to enhance both local and systemic tumor control, including the abscopal effect. Compared with conventional radiotherapy, these advanced techniques leverage precise dose distributions, ultra-high dose rates, or the Bragg Peak physical properties to better protect normal tissues, mitigate radiation-induced lymphopenia, and favorably modulate the tumor microenvironment. Although preclinical studies and emerging clinical trials support the feasibility and efficacy of such combinations, further large-scale, well-designed clinical trials are required to validate their optimal application strategies and long-term benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.